Everolimus Can Overcome Trastuzumab Resistance In HER-2 Positive Early Breast Cancer

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle. The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news